Watch Ticker

X4 Pharmaceuticals, Inc. Common Stock

Go to X4 Pharmaceuticals, Inc. Common Stock Website

$1.65

0.04 (2.48%)

Live

Previous Close

$1.61

Day Range

$1.6499 - $1.73

Previous Day Range

$1.54 - $1.635

Market Cap

$11.3 million USD

Day Vol.

277592

Previous Day Vol.

435718

Currency

USD

Primary Exchange

Nasdaq

X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the ...

Community

0 posts discussing

0

Watchers

0

Visitors

Recent News

X4 Pharmaceuticals - X4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN)

X4 Pharmaceuticals announced positive results from a six-month Phase 2 trial of its drug mavorixafor in treating chronic neutropenia. The drug durably increased participants' mean absolute neutrophil counts and enabled substantial reductions in G-CSF dosing while maintaining normal ANC levels.

Related tickers: XFOR.

Read Full Article

X4 Pharmaceuticals - X4 Pharmaceuticals Announces Positive Interim Clinical Data from Ongoing Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN) and Initiation of Pivotal Phase 3 CN Trial

100% of evaluable participants at Month 6 achieved target absolute neutrophil count (ANC) increase with once-daily, oral mavorixafor +/- stable-dose G-CSF as of the interim analysis data cut-off date

Related tickers: XFOR.

Read Full Article

Trending Tickers

Please sign in to view